The Association of 340B Program Drug Margins with Covered Entity Characteristics.

ABSTRACT: The 340B Drug Pricing Program aims to help facilities serving low-income and uninsured patients to stretch scarce resources by allowing covered entities to purchase outpatient drugs at federally mandated discounted rates while often receiving reimbursement for them at higher rates by commercial payers and Medicare. Despite increasing focus on the expansion and impact of the program, profit margins under 340B have not been fully explored. We aimed to examine drug-, facility-, and geographic-level factors that influence drug margins among 340B covered entities. We conducted a cross-sectional analysis of predictors of facility-level 340B margins for 5 drug classes in a multivariable regression model using 2021 data linked across multiple proprietary and public datasets. Regression results sho

SUBMITTER: Nordyke RJ 

PROVIDER: S-EPMC11938891 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature